文献速递妇产影像介入USMR

便携式超声引导高强度聚焦超声具备安全快速消融功能:子宫肌瘤前瞻性临床试验的短期与长期结果

Portable ultrasound-guided high-intensity focused ultrasound with functions for safe and rapid ablation: prospective clinical trial for uterine fibroids-short-term and long-term results.
PubMed 文献 · Eur Radiol · 2019-11-08

这项前瞻性临床试验纳入36例患者共59个子宫肌瘤,评估新型便携式超声引导高强度聚焦超声系统(具备先进靶向与波束偏转技术)治疗子宫肌瘤的有效性与安全性。治疗后MR显示即刻平均无灌注体积比为74.8±25.2%,肌瘤体积在1、3、5个月分别平均缩小17.3%、33.3%、45.1%,症状与生活质量显著改善,未出现安全性相关显著症状或并发症。长期随访中78.8%受访者对治疗满意。

要点

  • 即刻 post-HIFU MR 平均无灌注体积比(NPVR)为74.8±25.2%,肌瘤体积5个月平均缩小45.1%。
  • 治疗后子宫肌瘤相关症状与生活质量评分显著改善,未出现安全性相关显著症状或并发症。
  • 长期随访(平均32.2个月)中78.8%受访者对HIFU治疗满意。

核心结论

  • 该临床试验显示,具备先进功能的便携式超声引导高强度聚焦超声可能安全有效地治疗子宫肌瘤。
  • 长期随访超过2年时,约80%受访者对HIFU治疗满意。

研究设计与样本

  • 前瞻性临床试验,纳入2013年11月至2015年11月间36例患者共59个子宫肌瘤,平均年龄44.9±4.1岁。
  • 所有患者接受HIFU治疗,采用3D电子波束偏转技术。
  • 于HIFU前、HIFU后即刻、治疗后1个月及3(或5)个月行MR成像检查。
  • 分析指标包括无灌注体积比(NPVR)、肌瘤体积缩小率(FVS)、症状改善、量化生活质量评估及安全性;2017年7月至12月进行长期随访(平均32.2个月)。

关键影像表现/征象

  • 治疗子宫肌瘤体积范围7.5至274.4 cm3(平均69.8 cm3;SD 64.3 cm3)。
  • HIFU后即刻MR成像平均NPVR为74.8±25.2%。
  • 平均FVS在HIFU治疗后1个月为17.3%、3个月为33.3%、5个月为45.1%。
  • 平均治疗时间每个肌瘤44.6±28.2 min、每例患者72.9±31.4 min。

临床应用与阅片要点

  • 治疗后即刻MR测量的无灌注体积比(NPVR)可用于评估消融范围,本研究中平均为74.8±25.2%。
  • 随访MR可定量评估肌瘤体积缩小率,本研究中1、3、5个月平均分别为17.3%、33.3%、45.1%。
  • 作者认为,便携性、靶向预测、电子波束偏转和交错扫描等先进功能可能有助于增强超声引导高强度聚焦超声的临床适用性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the efficacy and safety of a new portable ultrasound-guided high-intensity focused ultrasound system (USgHIFU) with advanced targeting and beam steering technology for the treatment of uterine fibroids.

METHODS: Fifty-nine uterine fibroids from 36 participants (mean age, 44.9 ± 4.1 years) were included from November 2013 to November 2015. All participants were treated with HIFU, with 3D electronic steering. MR imaging studies were performed before HIFU, immediately after HIFU, and 1 month and 3 (or 5) months after the HIFU treatment. The non-perfused volume ratio (NPVR), fibroid volume shrinkage (FVS), symptom improvement, quantified life quality assessment, and safety were analyzed. A long-term follow-up was conducted in July to December 2017 (mean, 32.2 months).

RESULTS: The volume of the treated uterine fibroids ranged from 7.5 to 274.4 cm3 (mean, 69.8 cm3; SD, 64.3 cm3). The mean NPVR on the immediate post-HIFU MR imaging was 74.8 ± 25.2%. The mean FVS was 17.3% at 1 month, 33.3% at 3 months, and 45.1% at 5 months after HIFU treatment. The mean treatment time was 44.6 ± 28.2 min per fibroid and 72.9 ± 31.4 min per participant. Uterine fibroid-related symptoms and quality of life showed statistically significant improvement after the HIFU treatment. No significant symptoms related to safety or complications occurred. In the long-term follow-up, 78.8% of those surveyed were satisfied with their HIFU treatment.

CONCLUSION: This clinical trial showed that a portable USgHIFU with advanced functions may safely and effectively treat uterine fibroids.

KEY POINTS: • A portable compact ultrasound-guided high-intensity focused ultrasound (HIFU) can effectively and safely treat uterine fibroids. • Advanced functions, such as portability, targeted forecasting, electronic beam steering, and interleaved scanning, might be helpful in enhancing the clinical applicability of ultrasound-guided high-intensity focused ultrasound. • In the long-term follow-up of more than 2 years, approximately 80% of those surveyed were satisfied with their HIFU treatment.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lee JY, Chung HH, Kang SY, et al. Portable ultrasound-guided high-intensity focused ultrasound with functions for safe and rapid ablation: prospective clinical trial for uterine fibroids-short-term and long-term results. Eur Radiol. 2019. PMID: 31705252. doi:10.1007/s00330-019-06468-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。